Dr. Jacqueline Lui, Managing Director of Eagle IP Limited, gave a talk on “Patenting natural matters after Mayo and Myriad” at the 6th Annual Intellectual Property Seminar.
我們過去活動
Recommended Insights
Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical
2023年12月12日Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]
閱讀更多 >
China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)
2021年4月30日This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
閱讀更多 >
China Releases Draft Examination Guidelines for the new Patent Law
2020年12月4日The Chinese Patent Office (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but not limited […]
閱讀更多 >
Breaking News: China passes Fourth Amendment to the Chinese Patent Law
2020年10月19日After 12 years, the Fourth Amendment to the Chinese Patent Law has passed and will be in effect on 1 Jun 2021. After years of multiple draft amendments that moved in various directions, we FINALLY have some clarity on what patent protection is going to look like in China in the coming future. Many of […]
閱讀更多 >